Srinagarind Hospital experience in concurrent chemoradiation for 100 patients with stage IB2 to IVA uterine cervical cancer

Abstract

Weekly cisplatin (40 mg/m(2)) concurrent with pelvic irradiation for locally advanced cervical cancer was effective with acceptable toxicity in Thai women.

Acute toxicity in cervical cancer HIV-positive vs. HIV-negative patients treated by radical chemo-radiation in Zambia

“…However, this is in contrast to some available literature or protocols practised by certain oncology departments that omit the cisplatin from the protocol for this group of patients. [1][2][3] Acute side effects have not been studied on a large scale in cervical carcinoma patients who are infected with human immunodeficiency virus (HIV-positive) and are on radical chemoradiation. 3,4 Standards of treatment for HIV reactive cervical cancer patients have equally not been well defined.…”

Weekly gemcitabine and cisplatin concurrent with pelvic irradiation for primary therapy of cervical cancer: report of the first seven cases in Thai women

“…14 Pattaranutaporn et al 15 reported a regimen of weekly gemcitabine at 300 mg/m 2 for six courses for concurrent chemoradiation to treat 19 patients with stage IIIB cervical cancer and found that it was also tolerable and more effective. At 19.9 months of followup, the disease-free survival was 84.2%, and overall survival was 100%.…”